Medincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM: Major Subgroup Analysis Shows Reduced Pain and Opioid Use, and Accelerated Rehabilitation following Total Knee Replacement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 09 2024
0mins
Source: Yahoo Finance
Clinical Trial Results: A subgroup analysis of patients undergoing their first Total Knee Replacement (TKR) showed that those treated with F14/mdc-CWM experienced a 70% reduction in opioid use and significant improvements in pain, inflammation, and knee function compared to the control group.
Future Development Plans: Medincell plans to focus on this patient subgroup for future clinical development in 2025, pending FDA agreement, highlighting the potential of F14 as a non-opioid pain management solution amidst rising concerns over opioid addiction.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
